| T3146 | PD1-PDL1 inhibitor 2 | PD1-PDL1 inhibitor 2 is an inhibitor of the PD-1 (Programmed death- 1) /PD-Ll (Programmed death-ligand 1) protein/protein interaction, extracted from patent WO/2015034820 A1. |
| T3655 | PD-1/PD-L1 inhibitor 1 | PD1-PD-L1 inhibitor 1 (PD1-PD-L1-IN-1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a prot |
| T5S0777 | Phellodendrine chloride | Phellodendrine chloride has anti-nephritic activity, may be due to its ability to inhibit the proliferation or the migration of macrophages and cytotoxic T lymphocytes in the glome |
| T4696 | BMS202 hydrochloride (1675203-84-5(free base)) | PD-1/PD-L1 inhibitor 2 is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L1. Binding of BMS202 pr |
| T9902 | Atezolizumab | Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. |
| T9903 | Avelumab | Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity. |
| T9907 | Nivolumab | Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor |
| T9908 | Pembrolizumab | Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy. |
| T8470 | BMS-1001 | BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay). |
